TRPV2 and prostate carcinoma: CBGV is the most important antagonist of TRPV2 (EC50 = 1.7 μM), enough to be considered as a potential pharmacological agent to treat cancer because the overexpression of TRPV2 has been linked to several cancer types and cell lines such as urothelial cancers, prostate cancer, breast cancer, esophageal squamous cell carcinoma, and benign hepatoma, and in hepato-carcinomas and hematological malignancies, such as myeloma or acute myeloid leukemia [72].